Quantcast
Last updated on April 23, 2014 at 11:05 EDT

Latest Biologic Stories

2014-01-22 10:29:51

Levels of depression and anxiety in people with severe rheumatoid arthritis are higher than previously reported, according to new research. As a result of their findings, a multi-center team led by researchers at the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester, say that patients with severe active disease, who are waiting to go onto a biological therapy, should be routinely screened for depression by their doctors. The team, led by Professor...

2014-01-15 23:22:58

Xtalks presents an exciting live webinar on Thursday, January 30, 2014 at 11:00am EST (4pm GMT). Join keynote speaker Joerg Bluemel, Director of Toxicology within Biologics Safety Assessment / Translational Sciences at MedIummune for a one-hour discussion on nonclinical and clinical Safety Assessment of Biosimilars. Toronto, Canada (PRWEB) January 15, 2014 This webinar will focus on EMA and FDA regulatory perspectives on nonclinical and clinical safety assessment in biosimilars....

2014-01-14 12:26:37

PASADENA, Calif., Jan. 14, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing antibody-based products, today announced the appointment of inaugural members of its newly-formed scientific advisory board. The board will leverage its extensive experience in protein engineering to advise the company to help advance its proprietary monoclonal antibody (mAb) technology platform for the development of novel antibody-drug conjugates. "We are very proud to appoint...

2014-01-13 08:30:25

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2014-01-13 08:26:42

PETACH TIKVA, Israel, Jan. 13, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it will present new data based on a further analysis of results from its Phase IIb study of CF101 for the treatment of Rheumatoid Arthritis and interim data from its Phase II/III study of CF101 for the treatment of Psoriasis at the...

2014-01-09 23:20:23

The Biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (PRWEB) January 09, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major...

2014-01-09 08:26:28

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc., a leading Contract Manufacturing Organization providing development and manufacturing services for biotechnology and pharmaceutical companies, announced today its new product offering, Corynex®, to produce secreted, soluble, properly folded proteins from microbial fermentation. In addition, the company announced the successful finalization of the production process for a therapeutic protein primed to enter a Phase I...

2014-01-08 20:21:24

Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety WASHINGTON, Jan. 8, 2014 /PRNewswire-USNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) asking the agency to require biosimilars to bear nonproprietary names that are similar to, but not the same as, those of their reference products or of other biosimilars. The Petition states...

2014-01-08 16:26:12

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase(TM) 2014 conference next week in San Francisco, as follows: Date: Wednesday, January 15, 2014Time: 9:30 a.m. (PT)/12:30 p.m. (ET)Location: Room-Mission II, Parc 55 Wyndham San Francisco Union...